CDXS vs GEVO vs BEAM vs NTLA vs SGMO

For growth investors, Gevo, Inc.

(GEVO) is the stronger pick with 849. 3% revenue growth year-over-year, versus -67. 2% for Sangamo Therapeutics, Inc. (SGMO). Analysts rate Codexis, Inc. (CDXS) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Beam Therapeutics Inc.

(BEAM) delivered a total return of -55. 6%, compared to -99. 0% for Sangamo Therapeutics, Inc. (SGMO). Over 10 years, the gap is even starker: BEAM returned +67. 8% versus GEVO's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Gevo, Inc.

(GEVO) is the lower-risk stock at 1. 64β versus Intellia Therapeutics, Inc. 's 2. 37β — meaning NTLA is approximately 44% more volatile than GEVO relative to the S&P 500. On balance sheet safety, Intellia Therapeutics, Inc. (NTLA) carries a lower debt/equity ratio of 14% versus 145% for Codexis, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Gevo, Inc.

(GEVO) is pulling ahead at 849. 3% versus -67. 2% for Sangamo Therapeutics, Inc. (SGMO). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to 27. 4% for Intellia Therapeutics, Inc.. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gevo, Inc.

(GEVO) is the more profitable company, earning -21. 1% net margin versus -609. 9% for Intellia Therapeutics, Inc. — meaning it keeps -21. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GEVO leads at -11. 7% versus -651. 7% for NTLA. At the gross margin level — before operating expenses — SGMO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Gevo, Inc.

(GEVO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Intellia Therapeutics, Inc. (NTLA) carries a higher beta of 2. 37 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GEVO: -98. 6%, NTLA: -42. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CDXS (Healthcare) and GEVO (Basic Materials) and BEAM (Healthcare) and NTLA (Healthcare) and SGMO (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CDXS is a small-cap high-growth stock; GEVO is a small-cap high-growth stock; BEAM is a small-cap high-growth stock; NTLA is a small-cap high-growth stock; SGMO is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.